Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis
ConclusionSGLT2 inhibitors did not significantly increase the overall risk of cancer or the risks of bladder and breast cancers. However, the higher risk of renal cancer associated with SGLT2 inhibitors warrants concern. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - March 26, 2024 Category: Endocrinology Source Type: research
Randomized controlled trial of an app for cancer pain management
CONCLUSIONS: The primary obstacle encountered in the development of applications for managing cancer-related discomfort lies in the sensitive nature of the subject matter, potentially leading to patient apprehension regarding application usage for pain management. Consequently, meticulous attention to user preferences and anticipations is imperative, necessitating the creation of an application characterized by user-friendliness and medical efficacy.TRIAL REGISTRATION: Chinese Clinical Trials Registry ChiCTR1800016066; http://www.chictr.org.cn/showproj.aspx?proj=27153 . Date of Registration: 2018-05-09.PMID:38517559 | DOI:...
Source: Cancer Control - March 22, 2024 Category: Cancer & Oncology Authors: Lizhu Weng Wanlong Lin Xiuxian Lin Maobai Liu Jing Yang Source Type: research
